The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus☆
References (41)
- et al.
Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake
Metabolism
(1996) - et al.
Dose-response for glucagonostatic effects of amylin in rats
Metabolism
(1997) - et al.
Hypothesis: The essential role of glucagon in the pathogenesis of diabetes mellitus
Lancet
(1975) - et al.
Inhibitory effects of rat amylin on the insulin response to glucose and arginine in the perfused rat pancreas
Regul Pept
(1990) - et al.
In vitro autoradiographic localization of amylin binding sites in rat brain
Neuroscience
(1994) - et al.
Amylin injection causes elevated plasma lactate and glucose in the rat
FEBS Lett
(1991) - et al.
Islet amyloid polypeptide response to glucose, insulin, and Somatostatin analogue administration
Diabetes
(1990) - et al.
Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue
Diabetes Care
(1995) - et al.
Effects of pramlintide, an analogue of human amylin, on plasma glucose profiles in patients with IDDM
Diabetes
(1997) - et al.
Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemic control in patients with IDDM: Effects on plasma glucose profiles and serum fructosamine concentrations
Diabetologia
(1997)
Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man
J Clin Endocrinol Metab
Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinemic euglycaemic clamp in humans
Diabetologia
Acute effects of the human amylin analogue AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus
J Clin Endocrinol Metab
Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
Diabetologia
Amylin modulates insulin secretion in humans
Glucagon physiology and pathophysiology
N Engl J Med
Glucagon and its family revisited
Diabetes Care
Contribution to postprandial hyperglycemia and effects on initial splanchnic glucose cycling in glucose-intolerant or NIDDM patients
Diabetes
Glucagon: Role in the hyperglycemia of diabetes mellitus
Science
Wick-chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone
Nature
Cited by (104)
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
2021, Molecular MetabolismCitation Excerpt :Hence, in terms of glucagon and hepatic glucose production, individuals with diabetes, metaphorically, have one foot on the gas pedal and no brake. Pre-prandial pramlintide partially compensates for this, as it suppresses inappropriate glucagon secretion, thereby avoiding glucagon-induced hyperglycemia [155,161,162]. As has also been shown preclinically, pramlintide therapy in humans promotes long-term satiety [133] and reduces caloric intake in single-injection studies [163].
Glucagon-like peptide 1 (GLP-1)
2019, Molecular MetabolismCitation Excerpt :Amylin dose-dependently suppresses arginine-mediated glucagon secretion in rats [597] whereas pharmacological inhibition of amylin signaling enhances glucagon secretion [598]. Pramlintide, a synthetic amylin receptor agonist, improves glycemic control in diabetic patients via inhibition of postprandial glucagon secretion and inhibition of gastric emptying [599,600]. Interestingly, amylin does not affect glucagon secretion in isolated islets [601] nor in the perfused rat pancreas [602,603], suggesting that amylin regulation of glucagon is not cell autonomous.
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
2016, The Lancet Diabetes and EndocrinologyCitation Excerpt :The neuroendocrine hormone amylin, also known as islet amyloid polypeptide, is a 37-aminoacid peptide that is synthesised in the pancreatic β cells, stored in the pancreas with insulin (1:100), and is co-secreted with insulin in a high-frequency, pulsatile manner every 4 to 6 min.25 Amylin seemingly exerts its actions centrally by activating receptors in the area postrema, stimulating satiety centres and triggering efferent nervous impulses that inhibit glucagon secretion, and thereby reduce hepatic glucose production and delay gastric emptying.26–29 These actions imply that amylin reduces postprandial glucose excursions by modulating the rate of glucose influx into the circulation.
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
2016, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :Similar to GLP-1, it also inhibits post-prandial glucagon secretion, which contributes to hyperglycemia [72]. Pramlintide is a synthetic analog of amylin, with three amino acid substitutions to decrease toxicity while still enabling activation of amylin receptors [73,74]. Pramlinitide is injected at mealtimes thrice daily.
Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery
2024, Journal of Pharmacology and Experimental Therapeutics
- ☆
Supported by Amylin Pharmaceuticals, Oxford, UK, and San Diego, CA.